Figures & data
© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
Figure 1. Administration and dose-escalation information for GLP-1RAs with proven CVD benefit [Citation7–9]. CVD, cardiovascular disease; GI, gastrointestinal; GLP-1RA, glucagon-like peptide-1 receptor agonist.
![Figure 1. Administration and dose-escalation information for GLP-1RAs with proven CVD benefit [Citation7–9]. CVD, cardiovascular disease; GI, gastrointestinal; GLP-1RA, glucagon-like peptide-1 receptor agonist.](/cms/asset/865acafa-9564-45c3-a23d-24a7ab13998f/ipgm_a_2126235_f0001_c.jpg)
Table 1. Summary of CV risk factor outcomes in GLP-1RA CVOTs.
Table 2. Key data reported in meta-analyses of GLP-1RA CVOTs.
Table 3. Management of common GI AEs associated with GLP-1RAs with proven CV benefit.
Figure 2. Treatment decision-making infographic [Citation4–6].
![Figure 2. Treatment decision-making infographic [Citation4–6].](/cms/asset/a5fd4c15-61f8-4fa5-8894-760666e94455/ipgm_a_2126235_f0002_c.jpg)
ipgm_a_2126235_sm0998.mp3
Download MP3 Audio (9.3 MB)Data availability statement
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.